KSQ-001EX
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for KSQ-001EX, covering 2026-02-18 to 2026-02-18. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors [Phase 1, Phase 2]